N/A N=205 Depression Attention for Women Now (The DAWN Study)
Depressive Disorder
Primary: Depression Treatment Outcome — 0.96; 1.33 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=59 Desvenlafaxine vs. Placebo Treatment of Chronic Depression
Dysthymic Disorder · Dysthymia · Chronic Depressive Disorder
Primary: Hamilton Rating Scale for Depression (HDRS24) — 14.63; 14.21 units on a scale — p=0.09
Phase 4 N=30 Duloxetine Treatment in Elderly With Dysthymia
Depression · Dysthymic Disorder
Primary: Change in Hamilton Rating Scale for Depression (HAM-D, 24-item) From 0 Weeks to 12 Weeks. — 8 units on a scale — p=<0.001
N/A N=286 Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment
Parkinson Disease
Primary: Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part I (Mentation, Behaviour and Mood) — 2; 2 Points on a scale
Phase 4 N=480 Study Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD)
Major Depressive Disorder
Primary: Total Discontinuation - Emergent Signs and Symptoms (DESS) Score Over the First 2 Weeks of the Double-blind Phase — 4.1; 4.8; 5.3 scores on a scale
Phase 3 N=874 Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
Major Depressive Disorder
Primary: Time to Relapse Following Randomization to the Double-blind (DB) Phase: Estimated Probability (Percent) of Relapse at DB Day 185 — 30.2; 14.3 percent estimated…
Phase 3 N=48 Major Depressive Disorder With Mixed Features - Extension
Major Depressive Disorder
Primary: Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs) — 66.7 percentage of subjects
Phase 4 N=18 Wellbutrin XL for Dysthymic Disorder
Dysthymic Disorder
Primary: Hamilton Depression Rating Scale, 24 Items (HDRS) — 14.4; 13.3 units on a scale — p=<.05
Phase 2 N=143 SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline in Behavior Rating Inventory of Executive Function - Adult Version Global Executive Composite T-score (BRIEF-A GEC T) at Week 9, Last Observation…
Phase 4 N=34 Escitalopram in the Treatment of Dysthymic Disorder, Double Blind
Dysthymic Disorder
Primary: Hamilton-Depression Rating Scale (HDRS-24 Items) — 10.88; 16.41 units on a scale — p=0.10
Phase 4 N=65 Duloxetine for Chronic Depression: a Double-blind Study
Dysthymic Disorder · Depressive Disorder NOS
Primary: Hamilton Depression Rating Scale (HDRS) - 24 Total Score — 5; 10 Scores on a scale — p=.003
Phase 4 N=67 Continuous Oral Contraceptive Treatment in Premenstrual Dysphoric Disorder (PMDD)
Premenstrual Dysphoric Disorder
Primary: Pre-Post Change in Premenstrual Symptom Severity — 1.93; 1.73; 1.64 units on a scale
Phase 4 N=252 Evaluating the Effectiveness of Sertraline in Treating Women With Premenstrual Dysphoric Disorder
Premenstrual Dysphoric Disorder
Primary: Premenstrual Tension Scale (PMTS) — 22.3; 21.4; 15.6; 16.8 units on a scale — p=0.21
N/A N=42 Mommy-Baby Treatment for Perinatal Depression
Depressive Disorder, Major · Postpartum Depression
Primary: Change in Edinburgh Depression Scale From Baseline — 17.81; 17.9; 12.04; 11.41 units on a scale
Phase 3 N=416 Controlled-release Paroxetine in Major Depressive Disorder (Double-blind, Placebo-controlled Study)
Depressive Disorder
Primary: Adjusted Mean Change From Baseline in the Hamilton Depression Rating Scale (HAM-D; 17 Items) Total Score at Week 8 — -10.4; -12.8; -12.5 scores on a scale — p=<0.001
Phase 2 N=25 Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Panic Disorder With Comorbid Major Depression
Panic Disorder · Major Depressive Disorder
Primary: Panic Disorder Severity Scale (PDSS) — 6; 1 responders
Phase 4 N=439 Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364)
Major Depressive Disorder
Primary: Change From Baseline in Hamilton Depression Scale (HAM-D17) at Week 8 — 22.8; 22.4; -9.7; -7.4 Units on a scale — p=0.004
Phase 3 N=211 Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose
Major Depressive Disorder With Mixed Features
Primary: Mean Change From Baseline to the 6-week Study Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Scores — -20.5; -13.0 units on a scale — p=<0.0001
N/A N=120 Personalized Integrated Chronotherapy for Perinatal Depression
Depression · Postpartum Depression · Prenatal Disorder
Primary: Change in Depressive Symptoms — 1.6; 2.2 units on a scale
Phase 2 N=12 Treatment of Depersonalization Disorder With Transcranial Magnetic Stimulation (TMS)
Depersonalization Disorder
Primary: Cambridge Depersonalization Scale (CDS) — 6 responders (>50% reduction in CDS score)
Phase 3 N=1,149 A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder
Major Depressive Disorder
Primary: Phase C: Time-to-Relapse by Any Criteria as Defined in Blinded Addendum — 63.0; 63.0 days — p=0.5100
Phase 2 N=12 Pramipexole to Target "Anhedonic Depression"
Depression, Bipolar · Depression, Unipolar · Dysthymia
Primary: Dimensional Anhedonia Rating Scale (DARS) Score — 15.75; 33.08 score on a scale
Phase 2 N=504 MDD POC Study GSK372475 Subjects Depressive Disease
Depressive Disorder
Primary: Mean Change From Randomization at the End of the Treatment Phase in the MADRS Total Score — -16.9; -19.0; -20.5 Score on scale — p=0.485
Phase 4 N=126 Sustaining Remission of Psychotic Depression
Psychotic Depression
Primary: Number of Subjects at Risk of Relapse During the Randomized Phase. — 13; 34 Participants
N/A N=36 Neurophysiology of Postpartum Depression in an Experimental Model of Pregnancy and Parturition
Postpartum Depression
Primary: Blood-oxygen-level-dependent (BOLD) Response During Functional Magnetic Resonance Imaging (fMRI) z Statistic — 2.3; 2.0; 2.1; 1.7 z score — p=.27
N/A N=229 A Randomized Controlled Trial of PCIT-ED for Preschool Depression
Depressive Disorder, Major
Primary: Kiddie Schedule for Affective Disorders and Schizophrenia - Early Childhood (KSADS-EC) MDD Core Symptom Score — 1.74; 4.15 number of symptoms (0-9)
Phase 3 N=555 Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
Major Depressive Disorder
Primary: Early and Sustained (Antidepressant) Response (ESR) Rate — 17; 17; 17 Participants — p=1.000
Phase 4 N=7 Tranylcypromine Treatment of Bipolar Depression
Bipolar Disorder I or II
Primary: 29 Item Hamilton Rating Scale for Depression (HamD29) — 27.0; 5.8 Hamilton Depression score
Phase 2 N=1,197 SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Major Depressive Disorder
Primary: Change in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score From Augmentation Baseline (Week 8) to Week 16 (Double-blind Phase, Dose Response Evaluable Set)…
Phase 3 N=247 A Long-Term Study of Brexpiprazole in Patients With Major Depressive Disorder
Major Depressive Disorder
Primary: The Frequency of Subjects With Treatment-Emergent Adverse Events (TEAEs) — 96.8; 93.1 percentage of participants